Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ProgenaBiome
Studies have shown that a favorable microbiome can be the difference between response and non-response of certain cancer treatments such as PD-1 blockade inhibitors. As such the investigators propose to ensure a favorable microbiome in this patient by fecal microbiota transplant to enhance the efficacy of such a drug, Keytruda.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with metastatic mesothelioma deemed a candidate for PD-1 blockade inhibitor therapy
You may not be if
Patient unable/unwilling to comply with protocol
Patient deemed not a candidate for PD-1 Blockade inhibitor therapy
Clareo Health | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
